Cell death induced by i in a differentiated thyroid carcinoma cell line in vitro: necrosis or apoptosis?

Nuclear Medicine Communications

Volumn 27, Issue 4, 2006, Pages 353-358

  Marx, Kathrin ^a   Moka, Detlef ^a   Schomäcker, Klaus ^a   Fischer, Thomas ^a   Gabruk Szostak, Beate ^a   Kobe, Carsten ^a   Dietlein, Markus ^a   Schicha, Harald ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Apoptosis; Iodine 131; Necrosis; Thyroid carcinoma

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE CALCULATION; DRUG MEGADOSE; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; PAPILLARY CARCINOMA; THYROID CARCINOMA; CELL SURVIVAL; COMPARATIVE STUDY; NECROSIS; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE; THYROID TUMOR; TREATMENT OUTCOME; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IODINE RADIOISOTOPES; NECROSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 33746934210     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000199475.08407.e2     Document Type: Article

References (39)

1. Greig WR. The treatment of thyrotoxicosis with radioactive iodine. Scot Med J 1966; 11:307-314.
2. Dietlein M, Dressler J, Farahati J, Schicha H, Schober O. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2). Nuklearmedizin 2004; 43:115-120.
3. Horst W, Rosler H, Schneider C, Labhart A. 306 cases of toxic adenoma: clinical aspects, findings in radioiodine diagnostics, radiochromatography and histology; results of 131-I and surgical treatment. J Nucl Med 1967; 8:515-528.
4. Schicha H, Dietlein M. Radioiodine therapy in differentiated thyroid gland carcinoma. Zentralbl Chir 1997; 122:266-273.
5. Wieler H, Bartenstein P, Becker HP, Bell E, Decker P, Jakob R, et al. Guideline for therapy of malignant thyroid tumors: pleading for an actualisation. Nuklearmedizin 2004; 43:121-123.
6. Haq MS, McCready RV, Harmer CL. Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy. Nucl Med Commun 2004; 25:799-805.
7. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73:2013-2026.
8. Tomei LD, Cope RO. Current Communications in Cell and Molecular Biology. New York: Cold Spring Harbor; 1991; 3:410.
9. Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989; 83:865-875.
10. Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267:1445-1449.
11. Van Furth R, Van Zwet TL. Immunocytochemical detection of 5-bromo-2-deoxyuridine incorporation in individual cells. J Immunol Methods 1988; 108:45-51.
12. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68:251-306.
13. Albrecht HH, Creutzig H. Funktionsszintigraphie der Speicheldrüsen nach hochdosierter Radiojodtherapie. Fortschr Röntgenstr 1977; 125:541-551.
14. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998; 39:1551-1554.
15. Allweiss P, Braunstein GD, Katz A, Waxman A. Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication. J Nucl Med 1984; 25:755-758.
16. Spiegel W, Reiners C, Börner W. Einschränkungen der Speicheldrüsenfunktion nach hochdosierter Radiojodtherapie. Nuklearmediziner 1986; 3:159-166.
17. Dederichs B, Otte R, Klink JE, Schicha H. Volume reduction of the thyroid after radioiodine therapy in patients with autonomous goiter and Basedow's goiter. Nuklearmedizin 1996; 35:164-169.
18. Erdogan MF, Kucuk NO, Anil C, Aras S, Ozer D, Aras G, Kamel N. Effect of radioiodine therapy on thyroid nodule size and function in patients with toxic adenomas. Nucl Med Commun 2004; 25:1083-1087.
19. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif 1991; 24:203-214.
20. Radford IR, Murphy TK, Radley JM, Ellis SL. Radiation response of mouse lymphoid and myeloid cell lines. Part II. Apoptotic death is shown by all lines examined. Int J Radiat Biol 1994; 65:217-227.
21. Fabien N, Fusco A, Santoro M, Barbier Y, Dubois PM, Paulin C. Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer 1994; 73:2206-2212.
22. Menz R, Andres R, Larsson B, Ozsahin M, Trott K, Crompton NE. Biological dosimetry: the potential use of radiation-induced apoptosis in human T-lymphocytes. Radiat Environ Biophys 1997; 36:175-181.
23. Liu SQ, Saijo K, Todoroki T, Ohno T. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nature Med 1995; 1:267-271.
24. Shirahata S, Watanabe J, Teruya K, Yano T, Osada K, Ohashi H, et al. E1A and ras oncogenes synergistically enhance recombinant protein production under control of the cytomegalovirus promoter in BHK-21 cells. Biosci Biotechnol Biochem 1995; 59:345-347.
25. Teruya K, Yano T, Shirahata S, Watanabe J, Osada K, Ohashi H, et al. Ras amplification in BHK-21 cells produces a host cell line for further rapid establishment of recombinant protein hyper-producing cell lines. Biosci Biotechnol Biochem 1995; 59:341-344.
26. Feinendegen LE, Bond VP, Booz J, Muhlensiepen H. Biochemical and cellular mechanisms of low-dose effects. Int J Radiat Biol Relat Stud Phys Chem Med 1988; 53:23-37.
27. Feinendegen LE, Muhlensiepen H, Bond VP, Sondhaus CA. Intracellular stimulation of biochemical control mechanisms by low-dose, low-LET irradiation. Health Phys 1987; 52:663-669.
28. Feinendegen LE, Pollycove M. Biologic responses to low doses of ionizing radiation: detriment versus hormesis. Part 1. Dose responses of cells and tissues. J Nucl Med 2001; 42:17N-27N.
29. Pollycove M, Feinendegen LE. Biologic responses to low doses of ionizing radiation: Detriment versus hormesis. Part 2. Dose responses of organisms. J Nucl Med 2001; 42:26N-32N,37N.
30. Polliger B, Duhmke E. External radiotherapy of thyroid cancer. Onkologie 2001; 24:134-138.
31. Kikuchi S, Hiraide H, Tamakuma S, Yamamoto M. Expression of wild-type p53 tumor suppressor gene and its possible involvement in the apoptosis of thyroid tumors. Surg Today 1997; 27:226-233.
32. Majno G, Joris I. Apoptosis, oncosis and necrosis: An overview of cell death. Am J Path 1995; 146:3-15.
33. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. P53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362:847-849.
34. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP, et al. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 1994; 54:614-617.
35. Postgard P, Himmelman J, Lindencrona U, Bhogal N, Wiberg D, Berg G, et al. Stunning of iodide transport by (131)I irradiation in cultured thyroid epithelial cells. J Nucl Med 2002; 43:828-834.
36. Sabri O, Zimny M, Schreckenberger M, Meyer-Oelmann A, Reinartz P, Buell U. Does thyroid stunning exist? A model with benign thyroid disease. Eur J Nucl Med 2000; 27:1591-1597.
37. Kao CH, Yen TC. Stunning effects after a diagnostic dose of iodine-131. Nuklearmedizin 1998; 37:30-32.
38. Koch W, Knesewitch P, Tatsch K, Hahn K. Stunning effects in radioiodine therapy of thyroid carcinoma: existence, clinical effects and ways out. Nuklearmedizin 2003; 42:10-14.
39. Medvedec M. Thyroid stunning in vivo and in vitro. Nucl Med Commun 2005; 26:731-735.